You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Duration of overall response (Dor)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Squamous Cell Carcinoma Trial (DaRT seeds)

Recruiting
  • Recurrent Squamous Cell Carcinoma
  • DaRT seeds
  • Los Angeles, California
  • +11 more
Jan 29, 2023

Soft Tissue Sarcoma Adult, Angiosarcoma, Undifferentiated Pleomorphic Sarcoma Trial in Denmark, Norway, Sweden (Propranolol,

Recruiting
  • Soft Tissue Sarcoma Adult
  • +2 more
  • Aarhus, Denmark
  • +3 more
Jul 23, 2023

Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung Trial in Guangzhou (SI-B001, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Adenocarcinoma
  • Squamous Cell Carcinoma of Lung
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 5, 2023

Metastatic Urothelial Cancer Trial in China (Enfortumab vedotin)

Active, not recruiting
  • Metastatic Urothelial Cancer
  • Enfortumab vedotin
  • Beijing, China
  • +7 more
Aug 23, 2022

Multiple Myeloma (MM), DLBCL, Not Otherwise Specified, Double Hit Lymphoma Trial in Spain (IDP-121)

Recruiting
  • Multiple Myeloma (MM)
  • +5 more
  • Santander, Cantabria, Spain
  • +4 more
Jun 19, 2023

Advanced NSCLC Trial (BNT116, Cemiplimab)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jan 3, 2023

Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance Trial (RC48- ADC)

Not yet recruiting
  • Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
  • RC48- ADC
  • (no location specified)
Apr 29, 2022

Breast Cancer Trial (Injection of A166)

Not yet recruiting
  • Breast Cancer
  • Injection of A166
  • (no location specified)
Apr 20, 2022

Patients With Relapsed/Refractory Multiple Myeloma

Not yet recruiting
  • Relapsed and Refractory Multiple Myeloma (RRMM)
  • Non-Interventional
  • (no location specified)
Dec 21, 2022

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in United States (NVL-655)

Recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Orange, California
  • +13 more
Jan 31, 2023

Platinum-resistant Ovarian Cancer Trial in Shanghai (Oral Topotecan Combined With Anlotinib)

Not yet recruiting
  • Platinum-resistant Ovarian Cancer
  • Oral Topotecan Combined With Anlotinib
  • Shanghai, China
    Xinhua Hospital Affiliated to Shanghai Jiaotong University Schoo
Feb 12, 2023

Relapsed Refractory Multiple Myeloma Trial (REGN5458, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Relapsed Refractory Multiple Myeloma
  • (no location specified)
Feb 6, 2023

Cemiplimab to Historical Standard of Care in France

Recruiting
  • Cancer/Squamous Cell Carcinoma of Skin
  • France, France
    (unnamed)
Jun 6, 2022

Cervical Cancer Trial in Worldwide (Cemiplimab, ISA101b)

Recruiting
  • Cervical Cancer
  • Tucson, Arizona
  • +31 more
Jul 22, 2022

T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia Trial in Worldwide (Isatuximab SAR650984,

Terminated
Has Results
  • T-cell Type Acute Leukemia-Precursor
  • T-lymphoblastic Lymphoma/Leukaemia
  • Isatuximab SAR650984
  • +4 more
  • Atlanta, Georgia
  • +16 more
Mar 10, 2022

Metastatic Lung Non-Small Cell Carcinoma, EGFR T790M Trial in Seoul (Lazertinib)

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • EGFR T790M
  • Seoul, Korea, Republic of
    Samsung Medical Center
May 18, 2022

Metastatic Tumor Trial in Worldwide (SAR441000, Cemiplimab REGN2810)

Active, not recruiting
  • Metastatic Neoplasm
  • Fairway, Kansas
  • +20 more
Aug 11, 2022

Efficacy Trial in Suzhou (TAB008, Bevacizumab)

Completed
  • Efficacy
  • Suzhou, Jiangsu, China
    TOT
Jun 16, 2022

Hematological Malignancies Trial in Worldwide (Pembrolizumab/vibostolimab coformuation)

Recruiting
  • Hematological Malignancies
  • Pembrolizumab/vibostolimab coformuation
  • Duarte, California
  • +64 more
Jan 27, 2023

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Worldwide (NVL-520)

Recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Orange, California
  • +18 more
Oct 6, 2022

Adult Patients Who Initiate Systemic Treatment for

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional
  • Graz, Austria
  • +8 more
Sep 19, 2022

Colorectal Cancer, Liver Metastases, MSS Trial (Sinti+Rego+Cele)

Not yet recruiting
  • Colorectal Cancer
  • +2 more
  • (no location specified)
Jul 3, 2023

NSCLC Trial in Chongqing (Aumonertinib 165mg orally once daily and intrathecal chemo with pemetrexed)

Recruiting
  • Non-small Cell Lung Cancer
  • Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed
  • Chongqing, China
    chongqing University Three Gorges Hospital
Apr 11, 2023

Adult Patients Who Initiate Systemic Treatment for Relapsed or

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Non-Interventional
  • Graz, Austria
  • +8 more
Sep 19, 2022

Belantamab Mafodotin in Relapsed and/or Refractory Multiple

Recruiting
  • RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
  • Belantamab mafodotin
  • Albacete, Spain
  • +61 more
Aug 2, 2022